KLTO Stock Overview
A biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Klotho Neurosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.49 |
52 Week High | US$13.10 |
52 Week Low | US$0.26 |
Beta | -0.20 |
1 Month Change | 15.14% |
3 Month Change | -0.96% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -94.99% |
Recent News & Updates
Recent updates
Shareholder Returns
KLTO | US Biotechs | US Market | |
---|---|---|---|
7D | -17.5% | -2.1% | -2.1% |
1Y | n/a | -8.3% | 21.3% |
Return vs Industry: Insufficient data to determine how KLTO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how KLTO performed against the US Market.
Price Volatility
KLTO volatility | |
---|---|
KLTO Average Weekly Movement | 24.0% |
Biotechs Industry Average Movement | 11.2% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 18.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KLTO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KLTO's weekly volatility has decreased from 30% to 24% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 1 | Joe Sinkule | www.klothoneuro.com |
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.
Klotho Neurosciences, Inc. Fundamentals Summary
KLTO fundamental statistics | |
---|---|
Market cap | US$10.53m |
Earnings (TTM) | -US$4.21m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs KLTO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KLTO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$4.21m |
Earnings | -US$4.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.20 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did KLTO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/12 07:03 |
End of Day Share Price | 2025/01/10 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Klotho Neurosciences, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|